Shots:
- Under the terms of the agreement, Sandoz received the exclusive right to commercialize and distribute Ogivri, the biosimilar version of Herceptin & Abevmy, the biosimilar version of Avastin, across Australia for the treatment of various cancer indications
- Additionally, Sandoz AG will be held responsible to distribute Biocon’s biosimilar versions of trastuzumab and bevacizumab across Australia for the next 5yrs.. Earlier, Ogivri & Abevmy were distributed by another pharmaceutical country across Australia
- Herceptin is approved for the treatment of early-stage breast cancer, and Avastin is approved for the treatment of metastatic colorectal cancer (mCRC)
Ref: Biocon Biologics & Sandoz Image: Biocon Biologics & Sandoz | Press Release
Related News:- Sandoz’s Jubbonti (biosimilar, denosumab) Receives Health Canada’s Approval for the Treatment of Osteoporosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
